rTR Technovation

Our company is interested in understanding the biological mechanisms behind cases of remissions in various chronic diseases (diabetes, various cancers, coronary artery disease, etc) induced by a mechanotransduction-based therapy found in a private practice, in order to seek better and more effective treatments. Due to the unique nature of this therapy and the lack of existing technological tools to conduct research, we are developing a customized intravenous vascular-targeting nanoparticle to investigate various hypotheses as a starting point. This technology has various potential commercial applications and addresses unmet needs based on customer discovery on physicians and physician researchers.